Executive impairment determines XXXX medication response: implications for @entity4207 achievement.

@entity1 @entity73 @entity71 @entity7541 @entity4207 @entity2414 @entity2727
@entity2727 ( @entity7541 ) often ameliorates @entity71 ( @entity71 ) behavioral dysfunction according to indirect informant reports and rating scales. The standard of care behavioral @entity7541 titration approach seldom includes direct neuropsychological or @entity4207 assessment data to determine treatment efficacy. Documenting "cool" @entity2414 ( @entity2414 ) and "hot" self-regulation (SR) @entity73 could aid in differential diagnosis of @entity71 subtypes and determining cognitive and @entity4207 @entity7541 response. In this study, @entity1 aged 6 to 16 with @entity71 inattentive type (IT; n = 19) and combined type (n = 33)/hyperactive-impulsive type (n = 4) (CT) participated in double-blind placebo-controlled @entity7541 trials with baseline and randomized placebo, low @entity7541 dose, and high @entity7541 dose conditions. @entity2414 / SR measures and behavior ratings/classroom observations were rank ordered separately across conditions, with nonparametric randomization tests conducted to determine individual @entity7541 response. @entity1 were subsequently grouped according to their level of cool @entity2414 and hot SR circuit dysfunction. Robust cognitive and behavioral @entity7541 response was achieved for @entity1 with significant baseline @entity2414 /SR impairment, yet response was poor for those with adequate @entity2414 / SR baseline performance. Even for strong @entity7541 responders, the best dose for neuropsychological functioning was typically lower than the best dose for behavior. Findings offer one possible explanation for why long-term @entity4207 @entity7541 treatment gains in @entity71 have not been realized. Implications for @entity4207 achievement and medication titration practices for @entity1 with behaviorally diagnosed @entity71 will be discussed.
